Navigation Links
CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties -

RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced top-line results from a Phase I clinical trial of Tyrima(TM), its lead candidate for the treatment of depression and anxiety. In this study, Tyrima was safe and well tolerated. Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs.

The single-dose, placebo-controlled trial evaluated Tyrima in 41 subjects with doses escalating from 5 mg to 120 mg over the course of the study. Tyrima was well tolerated with no clinically significant adverse events even at the highest dose of 120 mg. Tyrima achieved high plasma concentrations that increased linearly with dose, and the favorable pharmacokinetic half-life should permit once or twice daily dosing. None of the safety and tolerability issues commonly associated with conventional monoamine oxidase A inhibitors (MAOIs) were seen in this study.

"The triple mechanism of MAOI antidepressants has the potential to provide enhanced efficacy to the 30% of patients who do not respond to current therapies, but use of these drugs has been limited by their propensity to cause serious side effects," said Dr. Atul Pande, chief medical officer of CeNeRx. "It is therefore encouraging that Tyrima, a selective and reversible MAO inhibitor specifically designed to avoid these side effects, demonstrated a promising safety profile in its first clinical trial, even at the highest dose. These results provide a strong foundation for proceeding to multiple dose safety studies."

Tyrima's unique mechanism elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that affect mood and anx
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
8. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/5/2008)...w England Journal of Medicine reaffirm,well-establ...RIVA(R),HandiHaler(R), RIDGEFIELD, Conn., and NEW...T (Understanding Potential Long-term Impacts on Fu...(R) HandiHaler(R) (tiotropium bromide,inhalation p...r up to 4,years as measured by FEV(1) (p<0.001) ve...
(Date:10/2/2008)...PC clinical success and expanded reimbursement ..., Oct. 2 /- Uroplasty, Inc.... first patients in a new,randomized, controlled mu...,PC neuromodulation system for the treatment of ov..., urge incontinence and frequency of urinary,voids...
(Date:10/2/2008)...RNewswire/ -- Athera Biotechnologies AB and Dyax,C...e entered into a,collaboration to discover and to ... treatment of cardiovascular inflammatory diseases...on of work by Athera,scientific founders, Professo...tutet. The research links naturally occurring anti...
(Date:10/1/2008)...1 /- Ironwood Pharmaceuticals, Inc.,t...ate equity financing.,This capital will be utilize...am evaluating linaclotide for the treatment of irr...d chronic constipation (CC), to invest,in a growin...s, and to,expand commercial capabilities. The fina...
Breaking Medicine Technology:Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 2Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 3Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 1Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 2Plexus Systems Ranks in Top Third of the 2007 Inc 5 000 with Three Year Sales Growth of 226 25 730 3Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 727 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 1Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 2Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 3Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 4Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 5Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 6Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 7Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 8Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 9Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 10Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 11Par Pharmaceutical Files Form 10 K for 2006 Company to Hold First Analysts Meeting September 28 2007 724 12Minimally Invasive Heart Surgery Research Wins N I H Award 721 1Minimally Invasive Heart Surgery Research Wins N I H Award 721 2
...TAWA, Canada – March 7, 2007 – Liponex...alizing in developing,advanced products related to...uo;good cholesterol,” today announced result...duct, CRD5. CRD5 is,being developed for the treatm...showed, to date, that CRD5 was safe and that the d...
...reduced the number of,new or enlarged lesions comp...tion at upcoming medical meeting -, CAMBRIDGE, Mas...-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma...CE trial, a Phase 2,randomized, double-blind, pla...ry endpoint in relapsing multiple sclerosis (MS),p...
Other Medicine Technology:Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
(Date:10/6/2008)... DIEGO, Oct. 6 /PRNewswire/ -- Developed in collab...ific Palisades, CA is introducing,Revolutionary Br...the,Plastic Surgery office of Dr. Steve Laverson t...(TM), is the first of its kind, and is based on,br... combined with,innovative proprietary software. Th...
(Date:10/6/2008)... OCI is pleased to announce the ... , Denver, Colorado (PRWE...eet the needs of its customers and target market, ...igned web site at www.oci.com. The site features i...sy navigability. , , ,“Human Resource, Benef...
(Date:10/6/2008)... Program offers up to 50 percent...ts. , Belleville, Ill. (V... is offering a new http://www.allsup.com/Health-Di...m __title__ Health Discount Program] to help milli...counted healthcare and medical services. The progr...
(Date:10/5/2008)...mbridge, MA...Free prescription drug samples distr...tudy by physicians from Cambridge Health Alliance ..., the first to look at free drug sample use among ...diatrics . , The authors, who also serve as res...Alpert Medical School of Brown University, found t...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:Free drug samples carry risks for children 2
...d problem solving, visual spatial processing, memo...severe alcoholism. Smoking is much more prevalent ...t the possible neurocognitive effects of cigarette... studied, despite evidence that long-term smoking ...
...e nephron-sparing surgery (NSS) is considered appr...s; however, it is still difficult to detect high n...ecific tumor markers have been identified for RCC,...is a variable predictor of lymph node and distant ...
...dings released by University of Florida doctors cl...fely avoid surgery after radiation therapy if they...r the cancer is under control or not, the research...d at the annual meeting of the American Society fo...
...or Vittorio Demicheli an Italian epidemiologist as...ving the use of Mumps, Measles and Rubella (MMR) v...k between MMR vaccination and autism or bowel dise...ots in children’s may cause Autism. This review lo...
Other Medicine News:Health News:A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma 2Health News:MMR Vaccination not linked to Autism 2
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium.
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model.
Short handled spatula for use through the side port stab incision. The malleable silver 0.5 mm tip can be shaped to the surgeon's preference for maximum control. Round serrated handle.
Used to mash overlooked pieces of nucleus into irrigating-aspirating unit and to control nucleus with second hand in phacoemulsification. 31 mm long narrow spatula blade. Round knurled handle with po
Medicine Products: